Where PhRMA is in the mifepristone debate; FDA warns that respirators may not deliver correct treatment

Taking stock of the drug industry, from the lab to the medicine chest

April 10, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Gabriela Bhaskar/The New York Times Where is PhRMA in the mifepristone debate? A judge's decision to suspend FDA approval of an abortion pill could impact pharma, but its lobbying association is staying on the sidelines. By Rachel Cohrs STAT+ | UnitedHealth's physician buying spree continues with takeover of Crystal Run With no fanfare, UnitedHealth Group has acquired Crystal Run Healthcare, a prominent physician group in New York. By Bob Herman FDA warns some Philips respirators may not deliver the right treatment On Friday, the Food and Drug Administration issued a recall for certain Philips CPAP respirators that were refurbished in an earlier recall. By Brittany Trang Caroline Yang for STAT Here's a new data point for cancer patients to consider: 'time toxicity' Some researchers say treatment studies should calculate how much of a patient's additional survival time would be spent simply getting care. By Charlotte Huff This biotech could one day make human eggs from scratch. But first, they're trying to rethink IVF Biotech startup Gameto's first product is called Fertilo, a set of ready-made reproductive support cells to mature eggs used in IVF. By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser